Please login to the form below

Not currently logged in
Email:
Password:

ProStraken gets German approval for cancer pain drug

Speciality pharmaceutical company ProStraken Group has received a marketing authorisation for Abstral

Speciality pharmaceutical company ProStraken Group has received a marketing authorisation for Abstral, its cancer pain drug, from the German Federal Institute for Drugs and Medical Devices (BfArM).

The company plans to launch Abstral, which was formerly branded as Rapinyl, in Germany and the UK at the beginning of 2009, and wider across Europe throughout the year.

Abstral is a fast-dissolving tablet for sub-lingual administration of fentanyl and is intended for the treatment of cancer pain in patients already receiving opioid analgesics.

Dr Wilson Totten, chief executive of ProStrakan, said: "Germany is an important market for Abstral and its approval by BfArM is a significant step forward towards its launch there. Our German operation is well advanced in its preparations for launch and we look forward to introducing German oncologists to this important product for cancer patients suffering from the debilitating effects of breakthrough pain."

ProStraken has in-licensed the exclusive rights to Abstral in Europe and North America from Orexo AB, a Swedish pharmaceutical company. The companies jointly launched the drug in Sweden in August 2008.

15th December 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics